Evolus back on track with Botox rival that was sidelined by manufacturing CRL

California biotech Evolus has had its resubmission for its Botox rival accepted by the FDA. (omegas/iStock/Getty Images Plus)

Evolus, which had its Botox rival sidelined by the FDA in May over CMC concerns, believes it has its manufacturing figured out and says it is back on track with an action date.

The Irvine, California-based biotech Wednesday announced the FDA had accepted its BLA resubmission and assigned its drug candidate DWP-450 a Feb. 2, 2019, PDUFA date.